help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Published ahead of print on April 17, 2003, doi:10.1164/rccm.200211-1359OC
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Online Supplement
Right arrow All Versions of this Article:
200211-1359OCv1
168/2/185    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Johnson, J. L.
Right arrow Articles by Mugerwa, R. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Johnson, J. L.
Right arrow Articles by Mugerwa, R. D.
American Journal of Respiratory and Critical Care Medicine Vol 168. pp. 185-191, (2003)
© 2003 American Thoracic Society

Original Article

Randomized Trial of Adjunctive Interleukin-2 in Adults with Pulmonary Tuberculosis

John L. Johnson, Emmanuel Ssekasanvu, Alphonse Okwera, Harriet Mayanja, Christina S. Hirsch, Joseph G. Nakibali, Dana Drzayich Jankus, Kathleen D. Eisenach, W. Henry Boom, Jerrold J. Ellner and Roy D. Mugerwa for the Uganda–Case Western Reserve University Research Collaboration

Division of Infectious Diseases, Department of Medicine, Case Western Reserve University School of Medicine and University Hospitals of Cleveland, Cleveland, Ohio; University of Arkansas for Medical Sciences, Little Rock, Arkansas; Division of Infectious Diseases, Department of Medicine, University of Medicine and Dentistry of New Jersey, Newark, New Jersey; Department of Medicine, Mulago Hospital and Makerere University; and National TB and Leprosy Control Programme, Kampala, Uganda

Correspondence and requests for reprints should be addressed to John L. Johnson, M.D., Division of Infectious Diseases, Department of Medicine, Case Western Reserve University, Room E-202, Tuberculosis Research Unit, 10900 Euclid Avenue, Cleveland, OH 44106–4984. E-mail: jlj{at}po.cwru.edu

Interleukin (IL)-2 has a central role in regulating T cell responses to Mycobacterium tuberculosis. Adjunctive immunotherapy with recombinant human IL-2 was studied in a randomized, placebo-controlled, double-blinded trial in 110 human immunodeficiency virus–seronegative adults in whom smear-positive, drug-susceptible pulmonary tuberculosis was newly diagnosed. Patients were randomly assigned to receive twice-daily injections of 225, 000 IU of IL-2 or placebo for the first 30 days of treatment in addition to standard chemotherapy. Subjects were followed for 1 year. The primary endpoint was the proportion of patients with sputum culture conversion after 1 and 2 months of treatment. After 1 month, the proportion of patients for whom sputum culture converted to negative was 17% for the IL-2 group compared with 30% in the control group (p = 0.14; {chi}2). After 2 months, 77% in the IL-2 group were culture negative compared with 85% of those receiving placebo (p = 0.29, {chi}2). Results were similar when patients with isoniazid monoresistance were included in the analysis. There were no differences in weight gain and no improvement in fever, cough, and chest pain between groups. One patient in each arm relapsed. IL-2 did not enhance bacillary clearance or improvement in symptoms in human immunodeficiency virus–seronegative adults with drug-susceptible tuberculosis.

Key Words: tuberculosis, pulmonary • antitubercular agents • immunotherapy • interleukin-2




This article has been cited by other articles:


Home page
 J. Clin. Microbiol.Home page
L. Li, C. S. Mahan, M. Palaci, L. Horter, L. Loeffelholz, J. L. Johnson, R. Dietze, S. M. Debanne, M. L. Joloba, A. Okwera, et al.
Sputum Mycobacterium tuberculosis mRNA as a Marker of Bacteriologic Clearance in Response to Antituberculosis Therapy
J. Clin. Microbiol., January 1, 2010; 48(1): 46 - 51.
[Abstract] [Full Text] [PDF]

Home page
 ACCP Crit Care Med Brd RevHome page
G. H. Karam
Infections in AIDS Patients and Other Immunocompromised Hosts
ACCP Crit Care Med Brd Rev, January 1, 2009; 20(0): 13 - 40.
[Full Text] [PDF]

Home page
 CVIHome page
D. J. C. Miles, M. van der Sande, S. Crozier, O. Ojuola, M. S. Palmero, M. Sanneh, E. S. Touray, S. Rowland-Jones, H. Whittle, M. Ota, et al.
Effects of Antenatal and Postnatal Environments on CD4 T-Cell Responses to Mycobacterium bovis BCG in Healthy Infants in The Gambia
Clin. Vaccine Immunol., June 1, 2008; 15(6): 995 - 1002.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
R. S. Wallis, H.-Y. Song, C. Whalen, and A. Okwera
TB Chemotherapy: Antagonism between Immunity and Sterilization
Am. J. Respir. Crit. Care Med., March 15, 2004; 169(6): 771 - 772.
[Full Text]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. J. Tobin
Tuberculosis, Lung Infections, Interstitial Lung Disease, Social Issues and Journalology in AJRCCM 2003
Am. J. Respir. Crit. Care Med., January 15, 2004; 169(2): 288 - 300.
[Full Text] [PDF]

Home page
 JWatch Infect. DiseasesHome page
IL-2 Does Not Improve Outcome in Pulmonary Tuberculosis
Journal Watch Infectious Diseases, August 8, 2003; 2003(808): 4 - 4.
[Full Text]

Home page
 Am. J. Respir. Crit. Care Med.Home page
P. F. Barnes
Immunotherapy for Tuberculosis: Wave of the Future or Tilting at Windmills?
Am. J. Respir. Crit. Care Med., July 15, 2003; 168(2): 142 - 143.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2003 American Thoracic Society 		  2nd Annual Dinner